Traws Pharma Q2 Cash Drops to $5M; FDA Clinical Hold Adds Pressure
TRAW sits 33% above its 52-week low of $0.43 on light trading volume (0.2× avg).
Summary
Traws Pharma reported Q2 2026 results with cash of $5.0 million as of June 30, down from $3.8 million at year-end 2025, reflecting continued cash burn despite April's $10 million upfront financing. The company disclosed an FDA clinical hold on its US IND for lead candidate tivoxavir marboxil due to toxicology data concerns, adding to the MHRA resubmission delay already known. Management expects to resubmit the MHRA package by end of Q3 2026 and aims to resolve the FDA hold by end of 2026. With a market cap under $10 million and a Nasdaq delisting notice from July 31, the cash runway and regulatory setbacks are critical for traders. The financing structure provides up to $50 million in additional capital but only upon milestone achievements, leaving near-term liquidity tight.
At the time of this announcement, TRAW was trading at $0.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.43 to $3.27. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.